摘要
目的基于数据库分析ADD3基因在弥漫性大B细胞淋巴瘤(Diffuse Large B Cell Lymphoma,DLBCL)中的表达情况及临床意义。方法基于Oncomine数据库进行荟萃分析,筛选出在DLBCL中的差异表达基因ADD3,并进一步分析其在mRNA及DNA水平上的表达差异,从GEO数据库下载含有DLBCL患者信息的数据集,对ADD3的表达量与患者的预后进行生存分析,并进一步对年龄、性别等亚组进行分析。利用GEPIA2在线分析工具对DLBCL样本中ADD3与c-Myc、Blc2、P53等基因进行相关性分析,通过癌症基因图谱数据库分析网站(UALCAN)对ADD3在DLBCL患者中的表达进行验证分析,DLBCL中ADD3在性别、年龄、种族、疾病阶段等不同亚组的表达量进一步进行验证分析。结果ADD3在荟萃分析中位于显著低表达基因的104位,生存分析显示ADD3的表达量与患者的生存预后显著正相关,相关性研究显示ADD3与Bcl2、c-Myc、P53等基因呈现弱相关性,亚组分析显示ADD3的表达量与性别、种族等因素无关,21~40岁年龄组表达量均高于41~60岁、61~80岁、81~100岁年龄组,对年龄亚组进一步进行生存分析,结果显示ADD3低表达组预后更差,与先前的分析结果一致。结论ADD3在DLBCL中低表达,且与患者预后呈现显著正相关性,有望作为DLBCL的独立预后标志物,为治疗和DLBCL提供参考靶点。
Objective To analyze the expression and clinical significance of ADD3 in diffuse large B-cell lymphoma(DLBCL)based on the database.Methods Based on the Oncomine database to conduct a meta-analysis,screen out the differentially expressed gene ADD3 in DLBCL,and further analyze its expression differences at the mRNA and DNA level,download a data set containing DLBCL patient survival information from the GEO database,and compare ADD3 Survival analysis is performed on the expression level and the prognosis of patients,and the subgroups such as age and gender are analyzed.Use the GEPIA2 online analysis tool to analyze the correlation between ADD3 and c-Myc,Blc2,P53 and other genes in DLBCL samples,and use the TCGA database analysis website(UALCAN)to analyze the ADD3 in DLBCL in different subgroups such as gender,age,race,disease stage,etc.The expression level is further verified and analyzed.Results ADD3 was located at 104 of the significantly low-expressed genes in the meta-analysis.Survival analysis showed that the expression of ADD3 was significantly positively correlated with the patient′s survival prognosis.Correlation studies showed that ADD3 was weak with genes such as Bcl2,c-Myc,and P53.The subgroup analysis shows that the expression of ADD3 has no reahtion shie with gender,race and other factors.The expression in the 21~40 age group is higher than that in the 41~60,61~80,81~100 age group.Survival analysis showed that the prognosis of the ADD3 low expression group was worse,consistent with the previous analysis.Conclusion ADD3 is low expressed in diffuse large B-cell lymphoma and has a significant positive correlation with the prognosis.It can be used as an independent prognostic marker for diffuse large B-cell lymphoma and an effective biological target for the treatment of DLBCL.
作者
石林
刘薇婉
张帅帅
任翠爱
SHI Lin;LIU Weiwan;ZHANG Shuaishuai;REN Cuiai(Weifang Medical University School of Clinical Medicine,Weifang Shandong 261000,China;State Key Laboratory of Experimental Hematology,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Science,Tianjin 300020,China;Department of Hematology,Weifang People′Hospital,Weifang Shandong 261000,China)
出处
《转化医学杂志》
2021年第2期65-69,82,共6页
Translational Medicine Journal
基金
国家自然科学基金(81700209)。